Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
November 10, 2023 01:30 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg,...
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
October 16, 2023 07:00 ET
|
Novo Nordisk A/S
Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension...
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
August 10, 2023 06:00 ET
|
Novo Nordisk A/S
Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in...
Mexico Insulin Drugs and Delivery Devices Market Revenues to Reach USD 566.91 million by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 09, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 09, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Mexico Insulin Drugs and Delivery Devices Market Report (2023-2028)," the market is estimated at USD...
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide
April 18, 2023 07:10 ET
|
Arch Biopartners
TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel...
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
April 05, 2023 09:00 ET
|
Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
April 05, 2023 07:55 ET
|
Aeterna Zentaris Inc
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...
Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease
February 07, 2023 07:05 ET
|
Arch Biopartners
TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
August 29, 2022 08:00 ET
|
Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...